GSK continues dealmaking spree with $950m 35Pharma acquisition
Less than 24 hours after inking a $1bn licensing deal with Frontier BioSciences, GSK has agreed to acquire Canadian biotech…
25 Feb 2026
RFK Jr faces legal challenge from 15 US states over childhood vaccine recommendations
More than a dozen US states have sued the Trump administration in a bid to reverse recent changes to childhood immunisation schedules that are alleged to be “unlawful” and “unscientific”.…
25 Feb 2026
Slate Medicines raises $130m in funds to progress anti-PACAP treatments
Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies. The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP…
25 Feb 2026
NorthX Biologics and Demeetra collaborate on GMP manufacturing and CLD
NorthX Biologics and Demeetra have entered a strategic partnership focused on integrated cell line development (CLD) and good manufacturing practice (GMP) manufacturing. The partnership brings together a high-titre glutamine synthetase…
24 Feb 2026
Gene editing takes centre stage in FDA’s new rare disease approval pathway
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new framework to spur the development of therapies for ultra-rare diseases.…
24 Feb 2026
GSK backs siRNA modality through $1bn Frontier deal
GSK has doubled down on its belief in the silent interfering RNA (siRNA) modality by inking a licensing agreement worth up to just over $1bn with Chinese company, Frontier Biotechnologies. Through this deal, GSK will hand over $40m…
24 Feb 2026
FDA accepts Beren Therapeutics’ NDA for Niemann-Pick disease
Beren Therapeutics has received the US Food and Drug Administration (FDA) acceptance to review its New Drug Application (NDA) for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset…